Late Breaking Trial IV: Feasibility And Clinical Importance Of Same Versus Next Day Discharge After Elective Transradial Percutaneous Coronary Intervention, The Rasadda-pci Trial - William Rollefson

↳ This is a section part of Moment: CRT 2017 : Late Breaking Trials: Session III

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$8.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Summary

Late Breaking Trial IV: Feasibility And Clinical Importance Of Same Versus Next Day Discharge After Elective Transradial Percutaneous Coronary Intervention, The Rasadda-pci Trial - William Rollefson at CRT 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$8.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Learning Objectives

Other Components in this Moment

Overview

Late Breaking Trial I: Lutonix® Paclitaxel-coated Balloon To Treat Obstructive Lesions In The Superficial Femoral And Popliteal Arteries: Preliminary Six-month Results From The SAFE-DCB Us Registry - Nicolas Shammas

Late Breaking Trial II: Biofreedom USA: The 12 Months Clinical and 9 Months Angio Results - Ron Waksman

Late Breaking Trial IV: Feasibility And Clinical Importance Of Same Versus Next Day Discharge After Elective Transradial Percutaneous Coronary Intervention, The Rasadda-pci Trial - William Rollefson

Late Breaking Trial III: New Drug-eluting Stents In Patients With Diabetes Mellitus And Multi-Vessel Disease (3d Registry) - Rafael Romaguera